Grimes & Company, Inc. Albireo Pharma, Inc. Transaction History

Grimes & Company, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	SELL	$18.54 - $37.29 $151,861 - $305,442	-8,191 Closed	0 $0
Q1 2022 May 06, 2022	BUY	$23.94 - $33.74 $196,092 - $276,364	8,191 New	8,191 $244,000
Q4 2021 Feb 01, 2022	SELL	$21.19 - $31.29 $174,647 - $257,892	-8,242 Closed	0 $0
Q3 2021 Nov 08, 2021	BUY	$27.36 - $35.98 $22,462 - $29,539	821 Added 11.06%	8,242 $257,000
Q2 2021 Aug 04, 2021	BUY	$28.9 - $36.87 $214,466 - $273,612	7,421 New	7,421 $261,000

865

Ticker ALBO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,612,500
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Grimes & Company, Inc. with notifications on news.